European Journal of Heart Failure

FEBRUARY 5, 2025

Methods and results TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6months. Clinical outcomes are reported in a non-randomized fashion from enrolment and from the end of the trial.

Heart Failure 67

Heart Failure Cardiomyopathy Atrial Fibrillation Arrhythmia 67

Journal of Cardiovascular Electrophysiology

NOVEMBER 29, 2023

Abstract Left ventricular assist device (LVAD) implantation is an established treatment for patients with advanced heart failure refractory to medical therapy. However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation.

Arrhythmia 75

Arrhythmia Heart Failure Ablation Outcomes 75

MIBHS

MARCH 31, 2025

Visiting the emergency room at the first sign of a heart attack can help begin treatment quickly and prevent complications like heart failure. Conclusion Although heart attack and cardiac arrest are often used interchangeably, they are separate conditions with different causes and treatments.

Cardiac Arrest 52

Cardiac Arrest Heart Attack Heart attacks Chest Pain 52

Cardiovascular Diabetology

FEBRUARY 23, 2024

Objective We aimed to assess the effect of SGLT2i on arrhythmias by conducting a meta-analysis using data from randomized controlled trials(RCTs). Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardioprotective effects via multiple mechanisms that may also contribute to decrease arrhythmias risk.

Sudden Cardiac Death 64

Sudden Cardiac Death Arrhythmia Atrial Flutter Heart Failure 64

The American Journal of Cardiology

JUNE 11, 2024

Publication date: Available online 11 June 2024 Source: The American Journal of Cardiology Author(s): Steven Brady, Eldon Matthia, Steve Antoine, Juan Aranda, William Miles, Juan Vilaro, Mohammad Al-Ani, Olusola Oduntan, Yi Guo, Yujia Li, Mustafa Ahmed, Alex Parker

Heart Failure 52

Heart Failure Arrhythmia Outcomes 52

Frontiers in Cardiovascular Medicine

JANUARY 14, 2024

Background Echocardiography-guided percutaneous intramyocardial alginate-hydrogel implantation (PIMAHI) is a novel treatment approach for heart failure (HF). During PIMAHI treatment, no sustained arrhythmia, pericardial, or pleural effusion occurred. We validated PIMAHI safety and efficacy in canine HF models. vs. 6.8 ± 0.2 mm,

Heart Failure 64

Heart Failure Outcomes Bicuspid/Mitral Arrhythmia 64

HeartRhythm

JANUARY 6, 2025

Atrial fibrillation (AF) is a common arrhythmia in patients with heart failure (HF). The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1].

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

HeartRhythm

APRIL 30, 2024

Cardiac resynchronization (CRT) with biventricular pacing (BVP) is recognized as an option to reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF). Left bundle branch area pacing (LBBAP) is an emerging role in achieving resynchronization in HFrEF and is thought to be a safe alternative to BVP.

Heart Failure 40

Heart Failure Arrhythmia Atrial Fibrillation Defibrillator 40

HeartRhythm

APRIL 30, 2024

Genetic predisposition to ventricular scarring is associated with heart failure and ventricular arrhythmia. Although many pathogenic variants have been shown to predispose patients to poor outcomes, the impact of many VUS remains uncharacterized.

Genetic predisposition 40

Genetic predisposition Heart Failure Arrhythmia Cardiomyopathy 40

HeartRhythm

OCTOBER 7, 2024

Arrhythmias can lead to cardiac arrest (CA) and heart failure. When intractable, heart transplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.

Heart Transplant 40

Heart Transplant Transplant Arrhythmia Cardiac Arrest 40

Frontiers in Cardiovascular Medicine

JANUARY 29, 2025

Myocarditis, an inflammation in the myocardium, can cause dilated cardiomyopathy, acute arrhythmia, and heart failure. This systematic review can determine MPOX infection outcomes and prepare appropriate treatment for patients with complications. Most cases were male and involved chest pain.

Chest Pain 40

Chest Pain Public Health Heart Failure Risk Factors 40

Heart BMJ

MAY 10, 2024

Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

Arrhythmia 40

Arrhythmia Myocardial Infarction Atrial Fibrillation Heart Failure 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

European Journal of Heart Failure

NOVEMBER 11, 2024

Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).

Heart Transplant 40

Heart Transplant Transplant Heart Failure Ablation 40

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

This systematic review of the literature aims to explore outcomes in the patients treated with conservative management vs. invasive strategy. with ST elevated myocardial infarction (STEMI), 3.41% with unstable angina, 0.56% with stable angina, and 0.11% were diagnosed with various types of arrhythmias. Approximately 48.5%

SCAD 75

SCAD Coronary Artery Bypass Graft Outcomes Myocardial Infarction 75

HeartRhythm

APRIL 30, 2024

Ventricular arrhythmias and heart failure are common presentations of cardiac sarcoidosis (CS). Guidelines support implantable cardioverter-defibrillator (ICD) for many CS patients with reduced ejection fraction, but arrhythmic outcomes are poorly understood.

Defibrillator 40

Defibrillator Heart Failure Arrhythmia Outcomes 40

MIBHS

JANUARY 15, 2025

Its effects on the heart are particularly alarming, as smoking significantly increases the risk of cardiovascular diseases (CVDs) and complicates medical procedures such as minimally invasive or bloodless heart surgeries. Smokings Impact on Surgery When heart surgery is necessary, smoking complicates both the procedure and recovery.

Coronary Artery Bypass Graft 52

Coronary Artery Bypass Graft Blood Clot Blood Pressure Plaque 52

Cardiology Update

JANUARY 2, 2024

European Heart Rhythm Association (EHRA) Congress Date: April 7-9, 2024 Location: Berlin, Germany and online Overview: The yearly gathering of the European Heart Rhythm Association (EHRA) unites scientists, healthcare professionals, and other stakeholders engaged in the global management of arrhythmias. Hashtag: #ESCPrev2024 5.

Heart Failure 111

Heart Failure Atherosclerosis Cardiovascular Imaging Non-Invasive Cardiology 111

Open Heart

JANUARY 17, 2024

We aimed to assess the 1-year clinical outcomes of the study population. The primary endpoint of this study was a composite of major adverse cardiovascular events (MACEs), including all-cause death, acute coronary syndromes, heart failure events, ischaemic strokes, sustained ventricular arrhythmias and acute kidney injury at 1-year follow-up.

Myocardial Infarction 96

Myocardial Infarction Quality of Life Heart Failure Arrhythmia 96

Open Heart

JANUARY 18, 2024

Objective Residual sequelae after surgical repair of tetralogy of Fallot (rTOF) affect clinical outcome. Methods Patients from the Swiss Adult Congenital HEart disease Registry were included. NT-proBNP, right atrial area and peak heart rate were independent predictors of outcomes.

Congenital Heart Disease 92

Congenital Heart Disease Congenital Heart Failure Exercise 92

DAIC

DECEMBER 29, 2023

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

Journal of Cardiovascular Electrophysiology

OCTOBER 16, 2024

This multicenter observational study evaluated the impact of LBBAP on clinical outcomes and improvements in echocardiographic parameters among patients with atrioventricular block and a reduced LVEF of 36%–50%. LBBAP significantly improved LVEF without causing fatal ventricular arrhythmias. No fatal ventricular arrhythmias occurred.

Arrhythmia 61

Arrhythmia Heart Failure Cardiomyopathy Pacemaker 61

Journal of Cardiovascular Electrophysiology

NOVEMBER 26, 2024

ABSTRACT Introduction Atrial fibrillation (AF) can cause or aggravate heart failure (HF). This study focused on the feasibility and outcomes of emergent AF ablation performed during hospitalization for acute HF. Arrhythmia recurrence was the primary endpoint. Catheter ablation (CA) is an effective treatment for AF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Hospital 40

Frontiers in Cardiovascular Medicine

JANUARY 16, 2024

Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. The clinical outcomes of catheter ablation and medical therapy were compared using the propensity score matched method. years following catheter ablation.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Cardiomyopathy Heart Failure 64

Hypertension Journal

MARCH 11, 2024

The effects on cause-specific cardiac outcomes are reported here.Methods:SSaSS was an unblinded, cluster-randomised trial assessing the effects of potassium-enriched salt compared with regular salt among 20 995 Chinese adults with established stroke and older age and uncontrolled hypertension. 0.99]); heart failure (9.14

Strokes 45

Strokes Stroke Outcomes Heart Failure 45

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

DAIC

JUNE 11, 2024

Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure. Leon added, “This new mitral-tricuspid valve center will mobilize a decade of specialized experiences among our contributing physicians to provide optimal clinical outcomes for our sickest patients.”

Tricuspid 111

Tricuspid Bicuspid/Mitral Heart Valves Innovation 111

Dr. Smith's ECG Blog

JULY 11, 2024

At this point, there was no improvement in LV function and he was out of the convalescent phase of his MI, so the decision was made to install an ICD for arrhythmia prophylaxis. He now has regular appointments with the heart failure team. The R waves have not recovered, however.

Outcomes 113

Outcomes Stenosis Outpatient Echocardiogram 113

HeartRhythm

APRIL 30, 2024

Nearly 50% of patients with AFib have comorbid obstructive sleep apnea (OSA), and 75% of OSA patients report some form of arrhythmia. Untreated OSA increases likelihood of poor outcomes for AFib patients including failed treatment, heart failure, and sudden cardiac death.

AFIB 40

AFIB Sudden Cardiac Death Outcomes Heart Failure 40

Journal of the American Heart Association

DECEMBER 24, 2024

Cardiovascular composite end points included major adverse cardiovascular events plus (a composite end point of allcause mortality, myocardial infarction, stroke, or heart failure) and cardiac arrhythmias (a composite end point of new onset atrial fibrillation and other atrial and ventricular arrythmias), all in the hospital setting.

Kidney Disease 45

Kidney Disease Arrhythmia Myocardial Infarction Atrial Fibrillation 45

Open Heart

AUGUST 7, 2023

Objective Ebstein’s anomaly is a rare congenital cardiac condition and data regarding pregnancy outcomes in this patient group are scarce. Pregnancy outcomes in women with Ebstein’s anomaly were examined. Pregnancy outcomes in women with Ebstein’s anomaly were examined. There were no maternal deaths.

Outcomes 40

Outcomes Congenital Heart Disease Tricuspid Heart Failure 40

Journal of the American Heart Association

MARCH 4, 2025

An increasing number of studies have shown the impact of social determinants of health (SDoHs) on different cardiovascular outcomes. In the setting of arrhythmias, specific SDoHs can increase the incidence of atrial fibrillation and adversely affect major outcomes in these patients.

Cardiovascular Disease 40

Cardiovascular Disease Peripheral Arterial Disease Congenital Heart Disease Coronary Artery Disease 40

Circulation

NOVEMBER 11, 2024

We aimed to investigate the impact of albumin levels and their changes on clinical outcomes among patients who were admitted to intensive care units due to cardiac causes.Methods:This is a retrospective, single-center, cohort study. Clinical outcomes were defined as 30-day mortality.Results:A total of 4,004 patients were enrolled.

Outcomes 40

Outcomes Coronary Artery Disease Heart Failure Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).

Atrial Flutter 40

Atrial Flutter Atrial Fibrillation Tachycardia Cardiomyopathy 40

Circulation

NOVEMBER 11, 2024

change in PC, initiation or escalation of diuretics, mortality, arrhythmias, heart failure hospitalization) over a 5-year period were obtained through chart review.Results:Deterioration of PC was significantly associated with worsening of all strain measures (p ≤0.05 Clinical events (e.g.,

Outcomes 40

Outcomes Congenital Physiology Heart Failure 40

Frontiers in Cardiovascular Medicine

OCTOBER 7, 2024

BackgroundEmerging evidence indicates a significant link between various immune cell types and the development of heart valve disorders. Mitral valve prolapse (MVP) is a common condition that can lead to heart failure, arrhythmias, and even sudden death. Currently, the role of immune cells in MVP is not well understood.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Valves Heart Failure Arrhythmia 59

CardiacWire

SEPTEMBER 25, 2024

That could have a major impact on cardiogenic shock outcomes, which rely heavily on blood pressure, and are associated with long/costly hospital stays and high mortality risks. That could be a big deal in the cardiogenic shock space, which many believe is still in need of more effective treatments.

Cardiogenic Shock 59

Cardiogenic Shock Blood Pressure Heart Failure Cardiac Function 59